MEA Checkpoint Inhibitors Market

MEA Checkpoint Inhibitors Market Size (2024 to 2029)

The checkpoint inhibitors market size in the Middle East & Africa was valued at USD 1.28 billion in 2023. The regional market is expected to reach USD 5.42 billion by 2029 from USD 1.63 billion in 2024, growing at a CAGR of 27.19 % during the forecast period.

Checkpoint inhibitors are cancer medicines that target the checkpoints. As a result, the market for checkpoint inhibitors is expected to grow as cancer incidence rates rise.

MARKET DRIVERS

The checkpoint inhibitors market in this region is expected to be driven by the Y-O-Y rise in the various types of malignancies and the increase in the geriatric population in the Middle East and Africa, particularly in the market and rising economies. In addition, during the forecast period, the rise in the number of cancer cases in MEA is expected to accelerate the growth of the checkpoint inhibitors market in this region. Lung, prostate, bowel, and female breast cancer are the four most frequent kinds of cancer, accounting for 34 percent of all new cancer cases. Increased cancer prevalence in the Middle East and Africa demand for ideal therapeutics for cancer treatment, favourable reimbursement policies offered by manufacturers and insurance providers in some countries, and increased awareness of checkpoint inhibitors for cancer treatment due to positive results are a few key factors driving the growth of the Middle East and Africa checkpoint inhibitors market.

MARKET RESTRAINTS

However, the checkpoint inhibitor market in the MEA region is projected to be hampered by the high cost of cancer therapy using checkpoint inhibitors. There's a lot of pressure to keep costs low and demonstrate value. In addition, political uncertainty and ongoing economic stress are putting public health care funding in jeopardy in several countries. The lack of cost-effective cancer medicines has influenced the population's health and resulted in poor life expectancy. The drop is primarily due to the outbreak, which has resulted in tight containment measures such as social distancing, remote working, and the closure of industries and other commercial operations, all of which have impacted market growth.

This research report on the Middle East and Africa checkpoint inhibitors market has been segmented and sub-segmented into the following categories.

By Drug 

• PD-1 inhibitors
• PD-L1 inhibitors
• CTLA-4
• Chimeric Antigen Receptor T-cell
• Others

By Application 

• Lung cancer
• Renal cancer
• Blood cancer
• Bladder Cancer
• Hodgkin lymphoma
• Melanoma
• Others

By Country 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

The Middle East and Africa are projected to register a moderate share of the global checkpoint inhibitors market during the forecast period.

The UAE is predicted to have the largest market share in MEA during the forecast period. The presence of a large population of baby boomers in UAE necessitated the efficient treatment of various chronic diseases such as diabetes, skin cancer, urothelial carcinomas, Diabetes, skin cancer, urothelial carcinomas, and lung cancers are all on the rise, as is the prevalence of numerous chronic diseases like diabetes, skin cancer, urothelial carcinomas, and lung cancers.

KEY PLAYERS IN THE MEA CHECKPOINT INHIBITORS MARKET

Some of the key companies leading the Middle East & Africa Checkpoint Inhibitors Market are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma.